Ligand id: 8267

Name: milatuzumab

No information available.
Summary of Clinical Use
Both the FDA and EMA have granted milatuzumab orphan designation for the treatment of the rare diseases multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). Phase II clinical trials of milatuzumab for MM and CLL have been completed. A Phase I/II study of hLL1-DOX for relapsed non-Hodgkin's lymphoma and CLL is ongoing (NCT01585688).
Mechanism Of Action and Pharmacodynamic Effects
Milatuzumab is rapidly internalised following binding to CD74 on the surface of malignant B cells, and this ultimately leads to apoptotic cell death [2].